Made in China, Driving Innovation in Urologic Surgery: Professor Liqun Zhou Shares the Development and Application of Domestic Robotic Surgical Systems

Made in China, Driving Innovation in Urologic Surgery: Professor Liqun Zhou Shares the Development and Application of Domestic Robotic Surgical Systems

In the field of minimally invasive urologic surgery, Chinese physicians have long stood at the forefront of global innovationfrom pioneering retroperitoneoscopic approaches tailored to Chinese anatomical features to developing dual-console and remote robotic surgical systems that lead international standards. At the 2025 Annual Meeting of the Chinese Urological Doctor Association (CUDA), Professor Liqun Zhou, former Director of the Peking University Institute of Urology and current President of The First Affiliated Hospital of Henan University, delivered a compelling presentation titled “Application of Domestic Robotic Systems in Urologic Surgery – The IUPU Experience.” In an exclusive interview with UroStream, he shared the journey of IUPU’s development and clinical application of domestically produced surgical robots and offered insights into their transformative potential across urology.
Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

The 2025 Pujiang Prostate Cancer Academic Conference—jointly held with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai on June 27–28. At the conference, Professor Jianming Guo from Zhongshan Hospital, Fudan University, delivered a keynote presentation on “Managing Postoperative Complications After Prostate Cancer Surgery” and later shared additional insights in an interview with Oncology Frontier – UroStream, highlighting Zhongshan’s experience in perioperative enhanced recovery after surgery (ERAS) for prostate cancer patients.
ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

To live or to live well?” This Shakespearean dilemma continues to haunt many patients with bladder cancer. How to provide longer-lasting disease control while preserving the bladder through safer and more tolerable strategies has become a central challenge in urologic oncology. At the 2025 ASCO Annual Meeting, Professor Yijun Shen from Fudan University Shanghai Cancer Center presented the Phase II ReBirth study, which evaluates stratified bladder-sparing treatment strategies based on whether patients achieve clinical complete response (cCR) following neoadjuvant immunochemotherapy.